Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer Inc. (NYSE: PFE) and EMD Serono announced that the European Commission approved BAVENCIO® (avelumab) for first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.
BAVENCIO is the only immunotherapy shown to improve overall survival in advanced bladder cancer. In the JAVELIN Bladder 100 trial, the treatment significantly increased median overall survival to 21.4 months compared to 14.3 months for best supportive care alone. This approval marks a significant step in cancer treatment.
Pfizer and BioNTech SE have secured an advance purchase agreement with COVAX for up to 40 million doses of their COVID-19 vaccine, aimed at equitable distribution. The doses will be supplied throughout 2021, with the first expected in Q1, 2021. This initiative supports 92 low-income countries, ensuring access at a not-for-profit price. Both companies emphasize their commitment to providing affordable vaccines globally, aimed at combating the pandemic. The financial specifics of the agreement remain undisclosed.
Pfizer (NYSE:PFE) announced FDA approval for XALKORI® (crizotinib) to treat pediatric patients aged 1 and older with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). This marks the first biomarker-driven therapy for such patients, expanding treatment options for a rare form of non-Hodgkin lymphoma. Study ADVL0912 demonstrated an 88% objective response rate among 121 patients, with 39% maintaining response for at least 6 months. XALKORI previously received Breakthrough Therapy designation for this indication in May 2018.
Pfizer Inc. (NYSE: PFE) announced a $120 million investment in four clinical-stage biotech companies as part of its Pfizer Breakthrough Growth Initiative (PBGI). This initiative aims to invest up to $500 million in biotechnology firms developing clinical-stage assets aligned with Pfizer's focus areas, including oncology and rare diseases. Initial investments include ESSA Pharma ($10M), Trillium Therapeutics ($25M), Vedanta Biosciences ($25M), and Homology Medicines ($60M). Pfizer aims to leverage its resources to drive innovative therapies for patients.
Pfizer Inc. (NYSE: PFE) announced the dosing of the first participant in the Phase 3 CIFFREO study, investigating gene therapy candidate PF-06939926 for Duchenne muscular dystrophy (DMD). The trial aims to enroll 99 boys aged 4 to 7 across 15 countries, focusing on the efficacy and safety of the treatment. The primary outcome is the change in North Star Ambulatory Assessment score after one year. With no approved treatments currently available for DMD, the trial represents a significant milestone for patients and families affected by this condition.
ImaginAb Inc. has signed a multi-year, non-exclusive license agreement with Pfizer (NYSE: PFE) to provide the 89Zr CD8 Immuno-PET agent, aimed at imaging CD8 T cells in cancer patients. This partnership is expected to enhance drug efficacy identification, potentially shortening clinical trial durations and reducing costs. ImaginAb will supply clinical doses and offer technical support, receiving license fees and manufacturing payments in return. This agreement builds on a prior alliance focused on 89Zr CD8 Immuno-PET technology development.
Dewpoint Therapeutics has partnered with Pfizer (NYSE: PFE) to develop treatments for myotonic dystrophy type 1 (DM1), a rare genetic disorder. Dewpoint will receive an upfront payment and could earn up to $239 million in milestone payments if targets are met. Additionally, Dewpoint is set to receive royalties on any approved therapies. DM1 affects one in 8,000 to 20,000 individuals, leading to serious health issues. The collaboration aims to leverage biomolecular condensates to find novel solutions in treating this debilitating disease.
Pfizer (NYSE: PFE) will host webcasts featuring key discussions with its leadership at the 39th Annual J.P. Morgan Healthcare Conference, occurring virtually. CEO Albert Bourla will participate in a fireside chat on January 12, 2021, at 10:00 a.m. EST. Angela Hwang, Group President of Pfizer Biopharmaceuticals Group, is set to join a COVID-19 Vaccines Keynote Panel on January 13, 2021, at 12:45 p.m. EST. Archived copies of the webcasts will be available on Pfizer's investor website following their conclusion.
Pfizer (PFE) and OPKO Health (OPK) announced that the FDA has accepted the filing of the Biologics License Application (BLA) for somatrogon, a long-acting growth hormone for treating pediatric growth hormone deficiency (GHD). The FDA's target decision date is in October 2021. Results from a Phase 3 trial demonstrated somatrogon met primary endpoints, showing higher annual height velocity compared to daily somatropin. The therapy offers potential benefits by reducing the need for daily injections. Somatrogon has received Orphan Drug designation in the U.S. and EU.
Pfizer and BioNTech announced an agreement to supply an additional 100 million doses of their COVID-19 vaccine, COMIRNATY®, to the EU in 2021. This expands total doses to 300 million, following an earlier deal.
CEO Albert Bourla emphasized the commitment to rapid vaccine distribution as the virus continues to pose significant public health risks. The vaccine is produced in European manufacturing sites and is authorized for emergency use but not FDA-approved. Pfizer and BioNTech project potential supply of up to 1.3 billion doses worldwide by the end of 2021.